Abstract
Recent guidelines by the Heart Failure Society of America have recommended consideration for use of nitroprusside, nitroglycerin, or nesiritide in addition to diuretics to achieve hemodynamic and symptomatic improvement. This article reviews the results of previous studies evaluating the pharmacologic and clinical effects and safety profiles of these drugs in patients with heart failure.
MeSH terms
-
Acute Disease
-
Coronary Circulation / drug effects
-
Heart Failure / drug therapy*
-
Heart Failure / mortality
-
Heart Failure / physiopathology
-
Hemodynamics / drug effects
-
Humans
-
Infusions, Intravenous
-
Kidney / drug effects
-
Mitral Valve Insufficiency / drug therapy
-
Natriuretic Peptide, Brain / adverse effects
-
Natriuretic Peptide, Brain / pharmacology
-
Natriuretic Peptide, Brain / therapeutic use*
-
Nitrates / pharmacology
-
Nitrates / therapeutic use*
-
Nitroprusside / pharmacology
-
Nitroprusside / therapeutic use*
-
Vasodilator Agents / adverse effects
-
Vasodilator Agents / pharmacology
-
Vasodilator Agents / therapeutic use*
Substances
-
Nitrates
-
Vasodilator Agents
-
Natriuretic Peptide, Brain
-
Nitroprusside